NCT06246149 2026-03-04
ATOM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
Clinical Trials
15 trialsNCT06007690 2026-03-02
CoMpass
Aura Biosciences
Phase 3 Recruiting
NCT07015190 2026-02-18
Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences
Phase 3 Recruiting
NCT05502900 2025-05-15
AMUM
St. Erik Eye Hospital
Phase 3 Recruiting
NCT03172299 2025-03-24
PROTECT
Centre Hospitalier Universitaire de Nice
Phase 3 Completed
NCT06519266 2024-11-25
SCANDIUM-III
Vastra Gotaland Region
Phase 3 Recruiting
NCT02678572 2023-12-21
FOCUS
Delcath Systems Inc.
Phase 3 Completed
NCT05022901 2023-12-21
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Delcath Systems Inc.
Phase 3 Unknown
NCT02843386 2022-08-31
FOTEADJ
Institut Curie
Phase 3 Completed
NCT00324727 2021-06-21
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
Delcath Systems Inc.
Phase 3 Completed
NCT01989572 2020-07-07
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00680225 2017-04-12
Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
New England Retina Associates
Phase 3 Completed
NCT00036816 2012-09-24
Vaccine Therapy in Treating Patients With Melanoma of the Eye
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00110123 2012-09-24
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00000124 2006-06-02
Collaborative Ocular Melanoma Study (COMS)
National Eye Institute (NEI)
Phase 3 Unknown